Press Releases

01/12/2026

Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology

Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation’s premier academic medical centers, today announced a multi-year strategic collaboration aimed at transforming cancer care through advanced molecular profiling and data-driven insights. The collaboration will support NYU Langone Health’s Center for Mo...

01/12/2026

Northwestern Medicine Selects Tempus to Expand Genomic Testing

Collaboration will focus on the oncology patient population

Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient across cancer types, including patients with early-stage cancer diagnoses, access to genomic testing. Patients will benefit from a deeper understanding of their uni...

01/11/2026

Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion

Reported preliminary, unaudited Data and application revenue of ~$316 million for the full year 2025, representing ~31% year-over-year growth, with Insights (data licensing) growing 38%. 2025 Net revenue retention of ~126%

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bri...

01/11/2026

Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Full Year 2025 Select, Preliminary, Unaudited Financial Results Revenue of ~$1.27 billion, representing ~83% growth year-over-year, including ~30%...

01/08/2026

Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium. The meeting is being held on January 8–10 in San Francisco, California. “The research Tempus is presenting at ASCO GI refl...

01/06/2026

Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference

CHICAGO, January 6, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will participate in the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California. Tempus Founder and CEO Eric Lefkofsky will deliver a...

12/09/2025

Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9–12 at the Henry B. González Convention Center in San Ant...

11/18/2025

Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:30 AM ET....

11/14/2025

Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research

Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, nonprofit, private foundation dedicated to accelerating the development of innova...

11/05/2025

Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention...

NEWS

Media Coverage

Additional Partnerships